Yuanda Pharmaceutical won the "Best Hong Kong Stock Listed Company in Hubei" award ###
On June 28, 2022, the results of the 2022 (4th) Hubei Best Listed Company Selection were announced. Yuanda Pharmaceutical Group Co., Ltd. (0512.HK ) won the "Best Hong Kong Stock Listed Company in Hubei" award.
In order to promote the high-quality development of and discover value benchmark companies, the 4th Hubei Best Listed Company Selection is sponsored by Hubei Daily Media Group , jointly organized by the Hubei Daily Editorial Department and the Fulcrum Finance/Pulverum Magazine Editorial Department, and Huazhong Technology The University School of Economics , Wuhan University Regional Economic Research Center, Hubei Academy of Social Sciences Economic Research Institute, Chushang Think Tank, etc. serve as intellectual support units.
"Hubei's Best Hong Kong Listed Company" Award is based on the selection indicators of enterprise size, profitability, operating capabilities, investor recognition (online voting) and other selection indicators. Three award-winning companies were selected from the candidate companies. As one of the three best Hong Kong-listed companies, Yuanda Pharmaceutical's corporate value and high-quality development have been widely recognized.
As the leader of the pharmaceutical industry in Hubei Province, Yuanda Pharmaceutical has developed into a technologically innovative international pharmaceutical enterprise integrating pharmaceuticals, nuclear drugs, cardiovascular and cerebrovascular interventional diagnosis and treatment technology, and synthetic biology industry ( amino acid series, etc.) . At the operational level, in 2021, Grand Pharmaceutical achieved revenue of nearly HK$8.6 billion. It has deployed five technology R&D platforms and five R&D centers globally, with 106 projects under development, and invested approximately HK$2.3 billion in R&D. The five-year compound growth rate of parent net profit remains above 50%. At present, Yuanda Pharmaceutical has made in-depth layout in three innovative strategic directions: "precision interventional diagnosis and treatment of cardiovascular and cerebrovascular diseases", "interventional, nuclear medicine and immunotherapy anti-tumor" and "severe disease and anti-infection", and has dozens of items in reserve. Global innovative products are distributed in different stages from pre-clinical to marketing application, and the pipeline layout is reasonable, forming a good echelon effect. In addition, Yuanda Pharmaceutical continues to develop in multiple business fields represented by respiratory and facial features, cardiovascular and cerebrovascular emergency rescue, biological health products and high-quality raw materials, which has contributed greatly to the steady development of the company.
Recently, Yttrium [90Y] microsphere injection, a blockbuster product in the innovation pipeline of Yuanda Pharmaceutical for the treatment of liver malignant tumors, has been officially launched nationwide. The launch of this product will provide a large number of Chinese patients with liver malignant tumors with a The new and effective treatment method creates potential opportunities for surgical resection, fills the gap in local treatment of colorectal cancer liver metastases, and marks the arrival of a new international precision interventional treatment program in the field of liver malignant tumors in China. It is also the first step for Yuanda Pharmaceutical. Milestone progress in global innovative product pipeline.
As a technologically innovative international pharmaceutical company, Yuanda Pharmaceutical also actively assumes social responsibilities and always maintains communication with the capital market through regular performance conferences, online conference calls, offline road shows and company surveys. Actively engage in dialogue and communication with the capital market, timely update the group’s business status, strategic planning, R&D innovation and social responsibility initiatives, and strive to improve company transparency. Winning the award this time represents the capital market's recognition of Yuanda Pharmaceutical's comprehensive strength, and also instills confidence in the group's further development in technological innovation.
In the future, Yuanda Pharmaceutical will continue to adhere to the strategy of " global operation layout, dual-cycle operation and development of ", continue to increase investment in global innovative products and advanced technologies, and give full play to its industrial advantages and R&D strength to enrich and improve products. The pipeline and industrial layout will provide more advanced and diverse treatment options for patients around the world and bring more investment returns to shareholders.
Forward-Looking Statements
This press release may contain certain forward-looking statements. These statements are inherently risky and uncertain. The use of words such as "anticipate," "believe," "predict," "expect," "intend" and other similar words related to the Company are forward-looking statements. The Company undertakes no obligation to continually update these forward-looking statements.
These forward-looking statements are based on the Company's management's current beliefs, assumptions, expectations, estimates, forecasts and understandings of future events at the time the statements are made. These statements are not guarantees of future development and will be affected by risks, uncertainties and other factors, some of which are beyond the company's control and difficult to predict. Therefore, actual results may differ materially from the information contained in forward-looking statements due to future changes and developments in our business, competitive environment, political, economic, legal and social conditions.
The Company, its directors and employee agents disclaim (a) any obligation to correct or update forward-looking statements contained on this website; and (b) if any forward-looking statement fails to materialize or becomes incorrect. any liability.
